NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版

上传人:沧海****3 文档编号:121181596 上传时间:2020-02-18 格式:PDF 页数:36 大小:829.59KB
返回 下载 相关 举报
NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版_第1页
第1页 / 共36页
NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版_第2页
第2页 / 共36页
NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版_第3页
第3页 / 共36页
NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版_第4页
第4页 / 共36页
NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版_第5页
第5页 / 共36页
点击查看更多>>
资源描述

《NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版》由会员分享,可在线阅读,更多相关《NCCN临床实践指南_艾滋病相关卡波西肉瘤(2019.V1)英文版(36页珍藏版)》请在金锄头文库上搜索。

1、AIDS Related Kaposi Sarcoma Version 1 2019 October 19 2018 NCCN org NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Version 1 2019 10 19 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form wit

2、hout the express written permission of NCCN Continue Continue NCCN Guidelines Panel Disclosures NCCN Mary Dwyer MS Deborah Freedman Cass PhD Medical oncology Hematology Hematology oncology Radiotherapy Radiation oncology F Infectious diseases Surgery Surgical oncology Internal medicine Pathology Pha

3、rmacology Pharmacy Patient advocacy Discussion Writing Committee Member Lee Ratner MD PhD Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine Stacey Rizza MD F Mayo Clinic Cancer Center Michelle A Rudek PhD PharmD The Sidney Kimmel Comprehensive Cancer Center

4、 at Johns Hopkins Julian Sanchez MD Moffitt Cancer Center Jeff Taylor HIV Aging Research Project Palm Springs Benjamin Tomlinson MD Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Chia Ching J Wang MD UCSF Helen Diller Family

5、Comprehensive Cancer Center Sai Yendamuri MD Roswell Park Comprehensive Cancer Center Allison Hall MD PhD Duke Cancer Institute Kimberly L Johung MD PhD Yale Cancer Center Smilow Cancer Hospital Ann Klopp MD PhD The University of Texas MD Anderson Cancer Center Ann S LaCasce MD Dana Farber Brigham a

6、nd Women s Cancer Center Chi Lin MD Fred imaging is standard for staging of transplant associated KS cUseful in setting of clinical features ie fever dyspnea effusions concerning for KICS or KSHV associated MCD C reactive protein KSHV serum viral load SPEP IL 6 or IL 10 dSee Staging Classification f

7、or AIDS Related KS KS A AIDS RELATED KS STAGEd See First Line Therapy KS 2 Advanced cutaneous oral visceral or nodal disease See First Line Therapy KS 3 NCCN Guidelines Index Table of Contents Discussion Version 1 2019 10 19 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The N

8、CCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Version 1 2019 AIDS Related Kaposi Sarcoma Note All recommendations are category 2A unless otherwise indicated Clinical Trials NCCN believes that the best management

9、of any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged Printed by Maria Chen on 10 21 2018 10 50 05 PM For personal use only Not approved for distribution Copyright 2018 National Comprehensive Cancer Network Inc All Rights Reserved KS 2 Limited cu

10、taneouse Symptomatic and or Cosmetically unacceptable Stable disease or Response Progressive disease Relapsed or progressive diseasel Limited cutaneous Advanced cutaneous oral visceral or nodal disease See KS 3 eSee Principles and Goals of Therapy KS B fInitiation of ART may result in immune reconst

11、itution inflammatory syndrome IRIS within 3 6 months IRIS is characterized by marked lesional swelling increased tenderness and peripheral edema However ART should not be delayed or discontinued unless life threatening IRIS develops Reconstitution of immune function is important for obtaining and ma

12、intaining control or remission of KS gGlucocorticoids in any formulation should be avoided due to their association with KS progression However in cases of life threatening conditions including IRIS their use may be considered hSee clinicaltrials gov iSee Local Therapy KS C jSee Systemic Therapy KS

13、D kSee Principles of Radiation Therapy KS E lIf after initial response to therapy KS relapses or progresses repeat use of previously effective therapy may be considered particularly if response was durable Asymptomatic and Cosmetically acceptable Antiretroviral therapy ART f g Clinical trialh or Top

14、icalsi or Systemic therapyj or Intralesional chemotherapyi or RTe k or Local excision ARTf g and observe Symptomatic FIRST LINE THERAPYeRESPONSERELAPSED REFRACTORY THERAPY AIDS RELATED KS STAGE Continue ART and observe See Surveillance KS 4 NCCN Guidelines Index Table of Contents Discussion Version

15、1 2019 10 19 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Version 1 2019 AIDS Related Kaposi Sarcoma Note All recommendations are catego

16、ry 2A unless otherwise indicated Clinical Trials NCCN believes that the best management of any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged Printed by Maria Chen on 10 21 2018 10 50 05 PM For personal use only Not approved for distribution Copyright 2018 National Comprehensive Cancer Network Inc All Rights Reserved KS 3 Advanced cutaneous oral visceral or nodal diseasee ARTf g Clinical trialh or Systemic therapyj Response Stable or progress

展开阅读全文
相关资源
相关搜索

当前位置:首页 > 医学/心理学 > 肿瘤学

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号